Table 5.
Description of overall cardiovascular toxicity observed with pazopanib treatment
| Entire Study Population (n) | 35 |
|---|---|
| Any CV toxicity | 24 (69%) |
| Any CV toxicity excluding hypertension | 12 (34%) |
| Grade 1 QTc prolongation | 6 (17%) |
| Grade 2 QTc prolongation | 2 (6%) |
| Grade 3 heart failure | 1 (3%) |
| Grade 5 heart failure | 1 (3%) |
| Grade 3 atrial flutter | 1 (3%) |
| Grade 3 peripheral ischemia | 1 (3%) |
| Grade 2 hypertension | 3 (9%) |
| Grade 3 hypertension | 17 (49%) |
n number, CV cardiovascular, QTc corrected QT interval. Refer to Table 1 for grading definitions. Results displayed as number of patients (% of all study patients)